RYTM · NASDAQ · STOCK
Rhythm Pharmaceuticals, Inc.
$112.61
52W $74.50 – $122.20
62/100
$7.74B
-36.3
1.97
Is RYTM Bullish or Bearish?
Bullish.
Innellis AI committee rates Rhythm Pharmaceuticals, Inc. (RYTM) Buy with a composite score of 62/100
, based on 6 analysts with 67% agreement.
Last updated August 11, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +12.62 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -7.38 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 53.5% yoy -- genuine top-line momentum. Risk Analyst remains cautious — bollinger bandwidth of 16.3% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Revenue growing 53.5% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- Price-to-book of 26.5x prices in significant intangible value — Value
- ROE of only -80.5% -- cheap may mean cheap for a reason — Value
- Bollinger bandwidth of 16.3% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 11, 2026
Overall Committee Score
62/100
Agreement
67%
Analysts
6
Conviction
Contested
Sector Rank
Top 31%
of 192 Healthcare peers
Value Analyst
neutral
43
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− Price-to-book of 26.5x prices in significant intangible value
Growth Analyst
bullish
85
/ 100 · Low confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 53.5% YoY -- genuine top-line momentum
Technical Analyst
bullish
69
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
Risk Analyst
bearish
35
/ 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Bollinger bandwidth of 16.3% signals elevated volatility
Macro Analyst
bullish
78
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
bullish
65
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.22 across 9 articles, 14d)
Portfolio Manager
neutral
55
/ 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Technical Analysis
RSI (14)
59.9
Neutral
MACD Histogram
0.750
Bullish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Support
$96.35
Resistance
$115.56
Bollinger %B
0.81
Inside Bands
Price vs Moving Averages
EMA 9
$110.58
Above
EMA 21
$108.20
Above
EMA 50
$103.92
Above
EMA 200
$96.26
Above
Fundamental Analysis
Valuation
33
Profitability
25
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-36.3×
P/B Ratio
35.62×
PEG Ratio
9.08
Dividend Yield
0.00%
52W High
$122.20
52W Low
$74.50
Quality & Growth
ROE
-7278.5%
ROA
-4092.9%
Gross Margin
8900.1%
Operating Margin
-8362.4%
Revenue Growth YoY
—
Debt / Equity
0.02
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of -36.3 (inexpensive relative to a 15-40x range); Price-to-book of 35.6x; PEG ratio of 9.1 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -72.8%; Return on assets of -40.9%; Net margin of -85.6%; Gross margin of 89.0%; Current ratio of 3.45 (healthy short-term liquidity); Debt-to-equity of 0.02; Free cash flow per share is negative (-2.19); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full RYTM Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →